Today, with the development of the latest technologies, the treatment of serious diseases is becoming less and less problematic, however, it has long taken a very large volume of different samples and an even greater number of errors to determine the correct chemical compounds. As mentioned earlier, the world does not stand still and artificial intelligence could predict the composition of a new drug molecule just like any search query in a browser. OpenAI’s ChatGPT helps generate human-like responses for the analysis and synthesis of proteins, the building blocks of life and many medicines.
Will AI be able to correctly apply certain natural language algorithms that quickly analyze speech and predict the next step that can be applied to this biological data?
“Technologies like this will begin to cover areas of biology that are ‘untreatable,'” says Sean McClain, founder, and CEO of Absci Corp., a drug development company in Vancouver, Washington.
So if these algorithms work as hoped, they will bring new power to AI’s promise to transform drug discovery. There have already been previous attempts, but unfortunately, their use at the time faced limitations of technology or lack of data.
Since the technology is still in its early stages, most medical companies are more focused on using protein language models to improve known molecules. Absci and Helixon are also working with drugmakers to develop cancer drugs (companies positioning themselves as next-generation AI therapeutic discoveries)
A Merck representative said the company has entered into several collaborations to explore the potential of artificial intelligence in drug development. Helixon signed contracts with two major pharmaceutical companies last month to fight previously untreatable diseases, CEO says
Reference list: www.bizjournals.com